Company Filing History:
Years Active: 2024
Title: Olav Lapaire: Innovator in Biomarkers for Preeclampsia
Introduction
Olav Lapaire is a notable inventor based in Binningen, Switzerland. He has made significant contributions to the field of medical diagnostics, particularly in the area of preeclampsia. His innovative work focuses on developing methods to predict adverse outcomes related to pregnancy.
Latest Patents
Lapaire holds a patent titled "Ratios of sFlt-1 to P1GF or endoglin to P1GF as biomarkers for preeclampsia related adverse outcomes after birth." This invention is directed towards predicting the risk of a female subject developing postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method involves determining the levels of sFlt-1 and PlGF, or Endoglin and PlGF in samples taken before and after delivery. Additionally, the invention includes devices and kits designed to facilitate this method. He has 1 patent to his name.
Career Highlights
Throughout his career, Olav Lapaire has worked with prominent companies in the medical field, including Roche Diagnostics Operations, Inc. and Roche Diagnostics GmbH. His experience in these organizations has allowed him to contribute to advancements in diagnostic technologies.
Collaborations
Lapaire has collaborated with esteemed colleagues such as Martin Hund and Thomas Dieterle. Their combined expertise has furthered the development of innovative solutions in medical diagnostics.
Conclusion
Olav Lapaire's contributions to the field of biomarkers for preeclampsia highlight his role as an influential inventor. His work not only enhances the understanding of pregnancy-related complications but also paves the way for improved patient outcomes.